Aram Mangasarian, PhD

Chief Executive Officer

Mr. Mangasarian joined NOXXON in May 2010 as Chief Business Officer of NOXXON and was appointed CEO in July 2015. Aram brings over fifteen years' experience in the biotechnology industry to NOXXON.

Prior to joining NOXXON, Aram served as Vice-President Business Development for Novexel from October 2005 to March 2010. In this capacity he concluded the licensing agreement for North American rights to the NXL104 beta-lactamase inhibitor, now known as avibactam, with Forest Laboratories (NYSE:FRX) in January 2008. Aram was a member of the team that negotiated the acquisition of Novexel by AstraZeneca (NYSE:AZN) in March 2010.

From May 2000 to October 2005, Aram served in a variety of roles at ExonHit Therapeutics (now Diaxonhit, Euronext:ALEHT), eventually heading the business development function as Vice-President. He concluded a number of important agreements for ExonHit, in particular the strategic alliance with Allergan.

Jarl Ulf Jungnelius, MD, PhD

Chief Medical Officer

Jarl Ulf Jungnelius, MD, PhD worked at Celgene from 2007 to 2014 where he served as Vice President of Clinical Research and Development, Solid Tumors.

Prior to that post Dr. Jungnelius held leadership positions at Takeda, Pfizer and Eli Lilly & Company, where he was responsible for clinical development of oncology programs as well as involved in business development. Dr. Jungnelius held important responsibilities in the clinical development of several successful oncology drugs, including Abraxane®, Gemzar®, Alimta® and Revlimid®.

He is an oncologist with more than 25 years of clinical and research experience at both large pharmaceutical companies and academic organizations. Dr. Jungnelius is currently Chief Medical Officer at VAXIMM, Supervisory Board director of Isofol Medical AB, Biovica International AB and Monocl AB and has been a director at Oncopeptides AB since April 2011. He received both a Bachelor of Science degree and his MD from the Karolinska Institute in Stockholm Sweden.